Bahram Valamehr

2021

In 2021, Bahram Valamehr earned a total compensation of $6.5M as Chief Research and Development Officer at Fate Therapeutics, a 163% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$172,000
Option Awards$500,000
Salary$430,000
Stock Awards$5,375,416
Total$6,477,416

Valamehr received $5.4M in stock awards, accounting for 83% of the total pay in 2021.

Valamehr also received $172K in non-equity incentive plan, $500K in option awards and $430K in salary.

Rankings

In 2021, Bahram Valamehr's compensation ranked 1,945th out of 12,405 executives tracked by ExecPay. In other words, Valamehr earned more than 84.3% of executives.

ClassificationRankingPercentile
All
1,945
out of 12,405
84th
Division
Manufacturing
734
out of 5,494
87th
Major group
Chemicals And Allied Products
280
out of 2,369
88th
Industry group
Drugs
239
out of 2,090
89th
Industry
Biological Products, Except Diagnostic Substances
71
out of 452
84th
Source: SEC filing on April 25, 2022.

Valamehr's colleagues

We found five more compensation records of executives who worked with Bahram Valamehr at Fate Therapeutics in 2021.

2021

J Wolchko

Fate Therapeutics

Chief Executive Officer

2021

Mark Plavsic

Fate Therapeutics

Chief Technology Officer

2021

Cindy Tahl

Fate Therapeutics

General Counsel

2021

Yu-Waye Chu

Fate Therapeutics

Chief Medical Officer

2021

Edward Dulac

Fate Therapeutics

Chief Financial Officer

News

You may also like